Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$37.17 USD
+0.81 (2.23%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $37.13 -0.04 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.17 USD
+0.81 (2.23%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $37.13 -0.04 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review
by Zacks Equity Research
The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.
Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
by Zacks Equity Research
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
by Zacks Equity Research
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 0% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Celldex (CLDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -11.43% and -91.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
by Zacks Equity Research
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More
by Zacks Equity Research
The biotech sector was in focus last week on key updates form Biogen (BIIB) and Prothena (PRTA).
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data
by Zacks Equity Research
Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -31.25% and -39.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
by Zacks Equity Research
The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
Do Options Traders Know Something About Celldex (CLDX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of -5.88% and 130.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
by Zacks Equity Research
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
Is the Options Market Predicting a Spike in Celldex Therapeutics (CLDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.